PMID: 8598700Feb 10, 1996Paper

Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients

Lancet
N SchmitzA Barge

Abstract

A randomised trial comparing filgrastim-mobilised peripheral blood progenitor cell (PBPC) transplants with autologous bone marrow transplantation (ABMT) for haematopoietic stem cell support has not been done. We compared the effects of filgrastim-mobilised PBPC or autologous bone marrow reinfused to lymphoma patients after high-dose chemotherapy in a prospective randomised multicentre trial. The trial was done at six centres in three European countries. After high-dose chemotherapy (carmustine, etoposide, cytarabine, and melphalan [BEAM protocol]) 58 patients with advanced Hodgkin's disease or high-grade non-Hodgkin lymphoma received either filgrastim-mobilised PBPC (n = 27) or bone marrow (n = 31) for haemopoietic reconstitution. The median number of days with platelet transfusions after grafting was 6 in the PBPC transplantation group and 10 in the ABMT group (estimate of treatment difference 5 days, 95% CI 3-7 days). Time to platelet recovery above 20 x 10(9)/L was 16 days in the PBPC transplantation group and 23 days in the ABMT group (p = 0.02). Time to neutrophil recovery above 0.5 x 10(9)/L was also reduced in the PBPC transplantation group (11 vs 14 days, p = 0.005). Patients randomised to PBPC transplantation needed fe...Continue Reading

References

Jan 22, 1971·Science·K B McCredieE J Freireich
Jan 1, 1994·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C A Uyl-de GrootF F Rutten

❮ Previous
Next ❯

Citations

Aug 9, 2012·Knee Surgery, Sports Traumatology, Arthroscopy : Official Journal of the ESSKA·A MarmottiC Tarella
Jul 28, 2005·Annals of Hematology·Michael Heuser, Arnold Ganser
Jan 22, 2004·Archives of Medical Research·Sally Arai, Hans-G Klingemann
Jul 3, 2013·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Koji KawamuraYoshinobu Kanda
Jul 23, 1998·Prostaglandins & Other Lipid Mediators·G L DeliliersM Marconi
Sep 30, 2000·Health Policy·S P McKenna, D Whalley
Dec 22, 1999·Archives of Medical Research·G J Ruiz-ArgüellesA Marín-López
Jan 1, 1997·La Revue de médecine interne·S Culine
May 4, 1999·Blood Reviews·R Bhidayasira, D Linch
Jun 26, 1999·Biochimica Et Biophysica Acta·J G Gribben
Jan 5, 2002·International Journal of Radiation Oncology, Biology, Physics·Micaela HernbergTom Wiklund
Dec 5, 1998·Seminars in Oncology Nursing·B A Bilodeau, K L Fessele
May 1, 1997·International Journal of Antimicrobial Agents·J J RusthovenA Hamilton
Aug 23, 2001·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·R H GreenA E Morrison
Feb 6, 1997·Transfusion Science·D H Pamphilon
Sep 11, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M van AgthovenC A Uyl-de Groot
Feb 21, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A J CroockewitH Zwierzina
Feb 19, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·G H LymanL Balducci
Sep 21, 2000·Critical Reviews in Oncology/hematology·N SabaA Keating
Feb 22, 2002·Critical Reviews in Oncology/hematology·Patrice Viens, Dominique Maraninchi
Jul 1, 1997·Critical Reviews in Oncology/hematology·V Rizzoli, C Carlo-Stella
Aug 10, 1999·Critical Reviews in Oncology/hematology·A Gratwohl, A Tyndall
Aug 10, 1999·Critical Reviews in Oncology/hematology·G Gahrton, B Björkstrand
Jan 14, 2009·Bone Marrow Transplantation·W BensingerJ M McCarty
Mar 25, 2009·Bone Marrow Transplantation·G KobbeR Haas
May 7, 2002·Nature Reviews. Cancer·Marie-Térèse Little, Rainer Storb
Jan 11, 2007·Bone Marrow Transplantation·M MianoUNKNOWN Paediatric Diseases Working Party of the European Group for Blood and Marrow Transplantation

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.